Abbott Receives FDA EUA and Launches Test to Detect Novel Coronavirus
Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the United States.
Read MorePosted by | Mar 25, 2020 | Emerging & Zoonotic Diseases, Infectious Diseases |
Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the United States.
Read MorePosted by | Mar 25, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
This is the first time the body’s general immune response to the new disease has been mapped.
Read MorePosted by Steve Halasey | Mar 24, 2020 | Emerging & Zoonotic Diseases, Infectious Diseases |
The agency’s EUA grants permission for Cepheid’s test to be used in high- and moderate-complexity CLIA-certified laboratories as well as in certain patient care settings.
Read MorePosted by Steve Halasey | Mar 24, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
The test is highly specific to covid-19 and targets several regions of the viral genome to minimize the impact on performance should there be possible future mutations.
Read MorePosted by | Mar 24, 2020 | Covid 19, Emerging & Zoonotic Diseases, Infectious Diseases |
If authorized, the new tests would increase the potential capacity to screen for covid-19 by thousands of tests per day.
Read More